key: cord-0871826-hel0oliz
authors: Zheng, Yi; Zhao, Jinxiang; Li, Jiaqi; Guo, Zhimou; Sheng, Jiajing; Ye, Xianlong; Jin, Gaowa; Wang, Chaoran; Chai, Wengang; Yan, Jingyu; Liu, Dong; Liang, Xinmiao
title: SARS-CoV-2 spike protein causes blood coagulation and thrombosis by competitive binding to heparan sulfate
date: 2021-10-29
journal: Int J Biol Macromol
DOI: 10.1016/j.ijbiomac.2021.10.112
sha: 030b161d484be44874850f4101edf1bcd83bb09b
doc_id: 871826
cord_uid: hel0oliz

Thrombotic complication has been an important symptom in critically ill patients with COVID-19. It has not been clear whether the virus spike (S) protein can directly induce blood coagulation in addition to inflammation. Heparan sulfate (HS)/heparin, a key factor in coagulation process, was found to bind SARS-CoV-2 S protein with high affinity. Herein, we found that the S protein can competitively inhibit the bindings of antithrombin and heparin cofactor II to heparin/HS, causing abnormal increase in thrombin activity. SARS-CoV-2 S protein at a similar concentration (~10 μg/mL) as the viral load in critically ill patients can cause directly blood coagulation and thrombosis in zebrafish model. Furthermore, exogenous heparin/HS can significantly reduce coagulation caused by S protein, pointing to a potential new direction to elucidate the etiology of the virus and provide fundamental support for anticoagulant therapy especially for the COVID-19 critically ill patients.

sciFLEXARRAYER (SCIENION, Berlin, Germany). The printed heparin was left on slide at 25°C overnight with 80% humidity. Before binding the slides were rinsed with TBST (20 mM Tris, 150 mM NaCl, 0.05% Tween 20, pH 7.4) for 2 min to remove the excess heparin and blocked with 1% BSA in TBST for 30 min. Binding assay were carried out essentially using protocols published previously [29] . In brief, for binding and competition of binding analyses, 100 μL protein solution in 1% BSA were applied to each subarray and the slide was left for 1.5 h at room temperature. After washing for three times with TBST, the slide was incubated with 100 μL diluted corresponding fluorescent antibody for 1 h at room temperature. The slide was washed three times with TBST, three times with distilled water, and dried with centrifugation.

To assess the effect of the mFc tag of the mouse IgG2a Fc-labelled S1 on heparin binding, three Fc-containing fluorescent antibodies, goat anti-mouse IgG, rabbit anti-His-tag and a mouse IgG2a Fc-containing anti-GST, were as the controls. No heparin binding signals were observed in any of the three control experiments (data now shown).

Competitive binding assays were carried out by three ways ( Table 1) . i) The pre-mixed solution of S1 and AT (or HCII) was incubated on microarray for simultaneously competitive binding; ii) AT or HCII was incubated with heparin on microarray for 1.5 h. After washing with TBST for three times, S1 was incubated for a further 1.5 h; iii) S1 was incubated for 1.5 h before AT or HCII was incubated for a further 1.5 h. As controls, S1, AT and HCII were also incubated respectively in parallel. AF488 labeled anti-mouse IgG was added and incubated for 1 h before addition of AF647 labeled anti-His-tag and incubation for another hour. The final binding signals of 8 (spots) × 4 (rows) repeating heparin spots in both competition experiments and control experiments were readout and averaged. The ratio of the mean value of competition experiment to that of the control experiment was calculated shown as percentage as a measure to indicate the degree of S protein competition. J o u r n a l P r e -p r o o f Concentration of His-AT in competitive binding is 1 μg/mL, and His-HCII of 2 μg/mL. The corresponding concentration of mFc-S1 were 2 μg/mL and 4 μg/mL. The concentration of control proteins was the same as that of competitive binding.

Microarray slides were scanned with GenePix 4300A fluorescence scanner (Molecular 

The anti-Xa and anti-thrombin activities of heparin were estimated by published methods [30] . 

Inhibitory experiment for S trimeric protein was similarly carried out except the following: For estimation of the amounts of trimeric S protein used in the inhibition and also in vivo zebrafish (see below) experiments, SARS-CoV-2 viral loads ranged from 6.41×10 2 to 1.34×10 11 copies/mL in clinical sputum samples [31] and 100 spike proteins in each viral particle [32] , based on the previous reports, were used for calculation. TI2-E-A1RHD25. The confocal images were analyzed using Nikon NIS-Elements AR-SP software. O-Dianisidine staining for globin was carried out as described previously [28] . In brief, the dechorionated zebrafish embryos were stained for around 15 min with a solution consisting of o-dianisidine (0.6 mg/mL), sodium acetate (0.01 mol/L), 0.65% hydrogen peroxide, and 40%

(v/v) ethanol in a petri dish in the dark. The embryos were then used directly for imaging analysis.

The procedure of hemostasis analysis was based on the preciously described work [33] with immediately after blood loss can be visualized from the wound and stopped when blood loss from the wound ceased.

J o u r n a l P r e -p r o o f Journal Pre-proof

We initially used carbohydrate microarrays [35] to investigate the effect of SARS-CoV-2 S protein on AT and HCII binding to heparin. We prepared heparin polysaccharide microarrays by printing 0.5 mg/mL heparin onto NHS-functionalized glass slides [36] . To simultaneously detect the respective binding signals, S1 protein was tagged with mFc and detected by fluorescence 488 nm while AT and HCII were labelled with His-tags and detected by 635 nm. As shown in Fig.   1A , the intense binding signals indicated strong binding avidity to heparin from all three proteins. Before further competition experiment, the binding curves of the three individual proteins were obtained. The binding signals were essentially saturated at protein concentrations of >1 μg/mL for AT (Fig. 1B) and >2 μg/mL for HCII (Fig. 1C) . Under saturated concentrations, all the binding sites of heparin immobilized on the microarray surface are considered to be occupied by AT or HCII, and under this condition, the competitive effect of the S protein becomes apparent and could be readily assessed. However, the mFc-S1 binding signals were saturated only at much higher concentration (40 μg/mL, Fig. 1D ).

Fluorescence binding signals of His-tagged AT and HCII (635 nm) and mFc-tagged SARS-CoV-2 S1 (488 nm). Binding curves of His-AT (B), His-HCII (C) and mFc-S1 (D) with serial concentrations were obtained from the fluorescence intensities of microspot images.

In competition experiment, the percentage of binding signals compared to the controls were used to estimate the competition ability ( Table 2) . The data showed stronger heparin binding J o u r n a l P r e -p r o o f Journal Pre-proof avidity of AT than S1 (96.4% and 62.0%, respectively). However, when S1 binding performed first, the binding signals of AT reduced to 76.3%, indicating that S1 can inhibit AT binding to heparin. S1 could bind heparin under all experimental conditions, even after AT 100% binding.

Compared with AT, the competition effect of S1 on HCII binding to heparin is more apparent.

With pre-mixed S1 and HCII, 73.3% of binding signals from HCII and 25.8% binding signals from S1 remained, indicating that the S1 binds to heparin less strongly. When S1 binding to heparin occurred first, a very high S1 binding signal was observed (92.7%). These results indicated that S protein of SARS-CoV-2 can interfere with anticoagulation activity of AT and HCII by competing with their binding to heparin, especially when S protein occupies heparin binding sites first. Table 2 . Competitive binding of SARS-CoV-2 spike protein S1, anticoagulation factors AT and HCII to heparin on microarrays.

Residual binding* Residual binding** AT S1 HCII S1

i) with premixed S1 & AT/HCII 96.4% ± 23.1% 62.0% ± 12.5% 73.3% ± 15.6% 25.8% ± 0.5%

ii) with AT/HCII followed by S1 104.8% ± 18.7% 24.3% ± 1.7% 76.9% ± 13.0% 11.4% ± 2.0%

iii) with S1 followed by AT/HCII 76.3% ± 21.0% 67.0% ± 27.8% 78.5% ± 11.4% 92.7% ± 18.0%

Means and standard deviations were obtained from 8 replicate points and three parallel experiments. The ratio of the mean value of the competition experiment to that of the control experiment was calculated shown as percentage to indicate the degree of S protein competition. * Concentrations used: S1 (2 μg/mL) and AT (1 μg/mL); ** Concentration used: S1 (4 μg/mL) and HCII (2 μg/mL).

We next investigated the effect of the trimeric S protein on coagulation pathways by in vitro heparin anticoagulation assays (Fig. 2) . Heparin IC 50 of anti-Xa and anti-thrombin activities were estimated as described [30] . With increased heparin concentrations, the activities of thrombin and factor Xa decreased and were almost completely inhibited via the AT and HCII pathways.

The IC 50 values of heparin on AT are low (~0.01 μg/mL for thrombin and ~0.025 μg/mL for Xa, J o u r n a l P r e -p r o o f Fig. 2A) . However, the IC 50 for HCII is relatively high (~0.5 μg/mL, Fig. 2D ). When S protein was added and incubated together with heparin at concentration of IC 50 value, heparin lost its anticoagulation-regulating ability in an S protein concentration-dependent manner. S protein at 8 μg/mL, estimated to be equivalent to viral concentrations of ~10 10 copies/mL, the viral load in the sputum of critically ill patients [31, 32] , could completely restore the coagulation effect of thrombin by the heparin-AT-thrombin pathway, and could restore 90% of Xa activity by the heparin-AT-Xa pathway (Fig. 2B, 2C) . For the heparin-HCII-thrombin pathway, S trimer at 32 μg/mL could completely inhibit HCII binding (Fig. 2E) . Compared with the AT pathway, HCII was less sensitive to the S protein as higher heparin concentration was required for activating itself. Further assays indicated that a higher concentration of HS (IC 50 ~7.5 μg/mL, Fig. 2F ) than that of heparin was needed to inhibit the activity of thrombin. However, a similar concentration of S protein (8 μg/mL) can restore the activity of thrombin by competitive binding to HS (Fig.   2G ).

J o u r n a l P r e -p r o o f 

Finally, we examined whether HS/heparin could alleviate the effect of S protein on blood coagulation and thrombosis in zebrafish. We co-injected S protein and HS or heparin into the CCV and subsequently injured at the PCV mechanically. We found that co-injection of S protein with heparin/HS significantly extended the bleeding time compared with injection of S protein only (Fig. 4A, 4B) . Co-injection of S protein with HS also reduced the total frequency (F) of thrombosis, caused by injection of S protein only as the control, from 100% to 42% in artery (DA), vein (PCV) and capillaries (ISV, DLAV, and CVP) (Fig. 4C) . More specifically, the thrombosis frequency was found to be reduced from 53% (19+34%) to 13% (5+8%) in large vessels (DA and PCV: DP), from 81% (47+34%) to 37% (29+8%) in capillaries (DLAV, ISV J o u r n a l P r e -p r o o f and CVP: DIC), and from 34% to 8% in both DIC and DP. These combined results suggest that HS/heparin could neutralize blood coagulation and thrombosis caused by S protein. 

In this study, we demonstrated that the SARS-CoV-2 spike protein can compete with anticoagulation factors AT and HCII bindings to heparin by blocking the inactivation process of thrombin or factor Xa. Once HS is bound by S protein, its dissociation is difficult, and HS can no longer interact with AT/HC II. Therefore, with the increased virus concentration in certain parts of the organs/tissues, such as microvascular, local HS can be exhausted, leading to exacerbated coagulation and other adverse consequences, especially in critically ill patients. This rapid coagulation response may be an additional independent factor for the inflammatory storm of severe COVID-19 patients.

J o u r n a l P r e -p r o o f

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

COVID-19 and its implications for thrombosis and anticoagulation

Incidence of venous thromboembolism in hospitalized patients with COVID-19

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study

Bidirectional Relation Between Inflammation and Coagulation

Platelet Gene Expression and Function in COVID-19 Patients

Endothelial cell infection and endotheliitis in COVID-19

Thrombosis as an intravascular effector of innate immunity

The endothelium in hypoxic pulmonary vasoconstriction

Comprehensive Landscape of Heparin Therapy for COVID-19

Anticoagulant properties of the vascular endothelium

Glycosaminoglycans and the regulation of blood coagulation

Heparin-binding domains in vascular biology

Directing thrombin

Control of the coagulation system by serpins. Getting by with a little help from glycosaminoglycans

Heparin Cofactor II: Discovery, Properties, and Role in Controlling Vascular Homeostasis

The preferred pathway of glycosaminoglycan-accelerated inactivation of thrombin by heparin cofactor II

Unfractionated Heparin, Low Molecular Weight Heparins, and Pentasaccharide: Basic Mechanism of Actions, Pharmacology, and Clinical Use

Structure and biological interactions of heparin and heparan sulfate

SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2

Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions

Sulfated polysaccharides effectively inhibit SARS-CoV-2 in vitro

Heparan sulfates from bat and human lung and their binding to the spike protein of SARS-CoV-2 virus

Heparin: A simplistic repurposing to prevent SARS-CoV-2 transmission in light of its in-vitro nanomolar efficacy

MicroRNA-10a/10b represses a novel target gene mib1 to regulate angiogenesis

Fatty Acid Binding Protein 11a Is Required for Brain Vessel Integrity in Zebrafish

Chemoenzymatic Synthesis of O-Mannose Glycans Containing Sulfated or Nonsulfated HNK-1 Epitope

How to analyze the anticoagulant and antithrombotic mechanisms of action in fucanome and galactanome?

Viral load of SARS-CoV-2 in clinical samples

Science Forum: SARS-CoV-2 (COVID-19) by the numbers. eLife. 9

Mechanical vessel injury in zebrafish embryos

An Optimized Method for Delivering Flow Tracer Particles to Intravital Fluid Environments in the Developing Zebrafish

Oligosaccharide microarrays for high-throughput detection and specificity assignments of carbohydrate-protein interactions

Microbial glycan microarrays define key features of host-microbial interactions

Vascular development in the zebrafish. Cold Spring Harb

Animal Models of Thrombosis from Zebrafish to Nonhuman Primates: Use in the Elucidation of New Pathologic the Development of Antithrombotic Drugs

Zebrafish as a model for normal and malignant hematopoiesis

The authors declare no competing financial interests.